Background: Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC. Methods: Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin ± bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a...
First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has show...
Despite developments in diagnosis and treatment, 20% of colorectal cancer (CRC) patients present wit...
Introduction: Colorectal cancer (CRC) is the third commonest cancer with nearly 1.4 million new case...
Background: Palliative systemic therapy is currently standard of care for patients with extensive me...
BACKGROUND:First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal ...
BACKGROUND: First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal...
<div><p>Purpose</p><p>We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissu...
PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict...
Colorectal cancer (CRC) is the second most frequent cause of cancer-related death worldwide. Detecti...
Introduction: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide...
Colorectal cancer represents a leading cause of cancer-related morbidity and mortality. Despite impr...
Background: Approximately 60% of patients with colorectal cancer (CRC) undergo either local recurren...
Colorectal cancer (CRC) is one of the worlds leading causes of cancer-related deaths in both men and...
BACKGROUND AND OBJECTIVES: Colorectal cancer is still one of the leading causes of cancer-related de...
Molina-Pinelo, Sonia et al.[Background] MicroRNAs (miRNAs) are involved in numerous biological and p...
First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has show...
Despite developments in diagnosis and treatment, 20% of colorectal cancer (CRC) patients present wit...
Introduction: Colorectal cancer (CRC) is the third commonest cancer with nearly 1.4 million new case...
Background: Palliative systemic therapy is currently standard of care for patients with extensive me...
BACKGROUND:First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal ...
BACKGROUND: First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal...
<div><p>Purpose</p><p>We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissu...
PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict...
Colorectal cancer (CRC) is the second most frequent cause of cancer-related death worldwide. Detecti...
Introduction: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide...
Colorectal cancer represents a leading cause of cancer-related morbidity and mortality. Despite impr...
Background: Approximately 60% of patients with colorectal cancer (CRC) undergo either local recurren...
Colorectal cancer (CRC) is one of the worlds leading causes of cancer-related deaths in both men and...
BACKGROUND AND OBJECTIVES: Colorectal cancer is still one of the leading causes of cancer-related de...
Molina-Pinelo, Sonia et al.[Background] MicroRNAs (miRNAs) are involved in numerous biological and p...
First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has show...
Despite developments in diagnosis and treatment, 20% of colorectal cancer (CRC) patients present wit...
Introduction: Colorectal cancer (CRC) is the third commonest cancer with nearly 1.4 million new case...